Efficacy and Safety of Teclistamab Followed by Autologous Stem Cell Transplant in Functional High-risk and Triple-class Refractory Multiple Myeloma.
作者信息
Sammartano Vincenzo, Ciofini Sara, Esposito Vangone Beatrice, Carrara Chiara, Bocchia Monica, Gozzetti Alessandro
机构信息
Hematology Unit, Azienda Ospedaliera Universitaria Senese, University of Siena, Siena, Italy.
Department of Clinical Medicine and Surgery, Federico II University Medical School, Naples, Italy.
出版信息
Mediterr J Hematol Infect Dis. 2025 Jul 1;17(1):e2025051. doi: 10.4084/MJHID.2025.051. eCollection 2025.
Abstract
摘要
相似文献
1
Efficacy and Safety of Teclistamab Followed by Autologous Stem Cell Transplant in Functional High-risk and Triple-class Refractory Multiple Myeloma.替雷利珠单抗联合自体干细胞移植治疗功能性高危和三重难治性多发性骨髓瘤的疗效与安全性
Mediterr J Hematol Infect Dis. 2025 Jul 1;17(1):e2025051. doi: 10.4084/MJHID.2025.051. eCollection 2025.
2
Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium.在既往接受过靶向BCMA治疗的复发/难治性多发性骨髓瘤患者中，替雷利珠单抗的疗效：来自美国多发性骨髓瘤免疫治疗联盟的一项多中心研究。
Blood Cancer J. 2025 Jun 25;15(1):111. doi: 10.1038/s41408-025-01314-9.
3
Efficacy, safety, and pharmacokinetics of teclistamab in Chinese patients with relapsed/refractory multiple myeloma from the China cohort of MajesTEC-1.在中国MajesTEC-1队列的复发/难治性多发性骨髓瘤患者中，替西妥单抗的疗效、安全性和药代动力学。
Cancer. 2025 Jan 1;131(1):e35665. doi: 10.1002/cncr.35665. Epub 2024 Dec 11.
4
Teclistamab for patients with heavily pretreated relapsed/refractory multiple myeloma and renal impairment.替雷利珠单抗用于经大量治疗的复发/难治性多发性骨髓瘤和肾功能损害患者。
Blood Adv. 2025 Jul 22;9(14):3408-3417. doi: 10.1182/bloodadvances.2025016059.
5
Teclistamab in Relapsed or Refractory Multiple Myeloma.特卡昔单抗治疗复发或难治性多发性骨髓瘤。
N Engl J Med. 2022 Aug 11;387(6):495-505. doi: 10.1056/NEJMoa2203478. Epub 2022 Jun 5.
6
Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma.在 Prospective LocoMMotion 研究中，三药暴露复发和/或难治性多发性骨髓瘤患者的真实世界临床实践中，替西罗莫司与现有治疗方案的疗效比较。
Adv Ther. 2023 May;40(5):2412-2425. doi: 10.1007/s12325-023-02480-7. Epub 2023 Mar 24.
7
Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study.特卡昔单抗，一种 B 细胞成熟抗原 × CD3 双特异性抗体，用于治疗复发或难治性多发性骨髓瘤（MajesTEC-1）：一项多中心、开放标签、单臂、1 期研究。
Lancet. 2021 Aug 21;398(10301):665-674. doi: 10.1016/S0140-6736(21)01338-6. Epub 2021 Aug 10.
8
Efficacy and safety of teclistamab in relapsed or refractory multiple myeloma: a systematic review and meta-analysis.替西妥单抗治疗复发或难治性多发性骨髓瘤的疗效和安全性：一项系统评价与荟萃分析
Ann Hematol. 2024 Dec;103(12):4901-4912. doi: 10.1007/s00277-024-06078-z. Epub 2024 Nov 8.
9
Comparative Effectiveness of Teclistamab Versus Real-World Physician's Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma.在三药暴露复发/难治性多发性骨髓瘤中，特里斯他单抗与现实世界中医生治疗选择的比较疗效：LocoMMotion 和 MoMMent 研究。
Adv Ther. 2024 Feb;41(2):696-715. doi: 10.1007/s12325-023-02738-0. Epub 2023 Dec 19.
10
Efficacy and safety of autologous hematopoietic stem cell therapy for refractory Crohn's disease: A systematic review and meta-analysis.自体造血干细胞疗法治疗难治性克罗恩病的疗效与安全性：一项系统评价和荟萃分析。
Medicine (Baltimore). 2017 Jun;96(26):e7381. doi: 10.1097/MD.0000000000007381.
本文引用的文献
1
Bispecific Antibodies and CAR T in Multiple Myeloma: Appropriate Selection of Patients and Sequencing.双特异性抗体和嵌合抗原受体T细胞疗法在多发性骨髓瘤中的应用：患者的合理选择与治疗顺序
Mediterr J Hematol Infect Dis. 2025 May 1;17(1):e2025045. doi: 10.4084/MJHID.2025.045. eCollection 2025.
2
Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management.多发性骨髓瘤：2024 年关于诊断、风险分层和治疗的更新。
Am J Hematol. 2024 Sep;99(9):1802-1824. doi: 10.1002/ajh.27422. Epub 2024 Jun 28.
3
A rational approach to functional high-risk myeloma.理性对待功能性高危骨髓瘤。
Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):433-442. doi: 10.1182/hematology.2023000443.
4
Definers and drivers of functional high-risk multiple myeloma: insights from genomic, transcriptomic, and immune profiling.功能性高危多发性骨髓瘤的定义因素和驱动因素：来自基因组、转录组和免疫分析的见解
Front Oncol. 2023 Oct 2;13:1240966. doi: 10.3389/fonc.2023.1240966. eCollection 2023.
5
Anti-BCMA novel therapies for multiple myeloma.用于多发性骨髓瘤的抗BCMA新型疗法。
Cancer Drug Resist. 2023 Mar 22;6(1):169-181. doi: 10.20517/cdr.2022.138. eCollection 2023.
6
Teclistamab in Relapsed or Refractory Multiple Myeloma.特卡昔单抗治疗复发或难治性多发性骨髓瘤。
N Engl J Med. 2022 Aug 11;387(6):495-505. doi: 10.1056/NEJMoa2203478. Epub 2022 Jun 5.
Zotero 插件